Press releases
Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.
2026
20 Nov 2026, 18:00
11 Nov 2026, 07:00 | Regulatory
· Closing of the €115 million licensing transaction with SERB
· Cash and cash equivalents amounted to 1,337.2 MSEK as of 30 September 2026
· The first commercial patient in Australia received a living-donor kidney transplant following treatment with Idefirix (Imlifidase)
10 Nov 2026, 22:00
5 Nov 2026, 13:00
4 Nov 2026, 10:00
30 Oct 2026, 17:00
28 Oct 2026, 12:00
23 Oct 2026, 19:30
· The 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful
· Graft and patient survival were 92% and 98%, respectively
· Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience